Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 2, 2005, Pages 217-233

  Robson, Simon C ^a,b   Wu, Yan ^b   Sun, Xiaofeng ^b   Knosalla, Christoph ^c   Dwyer, Karen ^b   Enjyoji, Keiichi ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibodies; CD39; Endothelial cell; Kidney; NTPDase; Platelets; Transplantation; Vasculature

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOVIRUS VECTOR; CD39 ANTIGEN; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 2; NUCLEOTIDASE; NUCLEOTIDE; PURINE P2 RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADVENTITIA; ANIMAL TISSUE; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC DISEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE INDUCTION; HUMAN; HUMORAL IMMUNITY; HYDROLYSIS; IN VIVO STUDY; INFLAMMATION; ISCHEMIA; LEUKOCYTE ACTIVATION; MOUSE; MUTANT; NONHUMAN; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PERFUSION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS; VASCULAR DISEASE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTIGENS, CD; APYRASE; GENE THERAPY; GRAFT REJECTION; HUMANS; ISCHEMIA; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; POSTOPERATIVE COMPLICATIONS; RABBITS; RATS; RATS, INBRED LEW; RECEPTORS, PURINERGIC P2; REPERFUSION INJURY; SWINE; SWINE, MINIATURE; THROMBOSIS; TISSUE AND ORGAN HARVESTING; TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS; VASCULITIS;

EID: 18044366362     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-869527     Document Type: Review

References (147)

1. Luthje J. Origin, metabolism and function of extracellular adenine nucleotides in the blood (Review). Klin Wochenschr 1989;67:317-327 (published erratum appears in Klin Wochenschr 1989;67:558)
2. Luthje J. Origin, metabolism and function of extracellular adenine nucleotides in the blood (Review). Klin Wochenschr 1989;67:317-327 (published erratum appears in Klin Wochenschr 1989;67:558)
3. Dubyak GR, Elmoatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides (Review). Am J Physiol 1993;265:C577-C606
4. Abbracchio MP, Burnstock G. Purinoceptors-are there families of P2X and P2Y purinoceptors (Review). Pharmacol Ther 1994;64:445-475
5. Harden TK, Lazarowski ER, Boucher RC. Release, metabolism and interconversion of adenine and uridine nucleotides: implications for G protein-coupled P2 receptor agonist selectivity. Trends Pharmacol Sci 1997;18:43-46
6. Weisman GA, Erb L, Garrad RC, et al. P2Y nucleotide receptors in the immune system: signaling by a P2Y(2) receptor in U937 monocytes. Drug Dev Res 1998;45:222-228
7. Robson SC, Enjyoji K, Goepfert C, et al. Modulation of extracellular nucleotide-mediated signaling by CD39/ nucleoside triphosphate diphosphohydrolase-1 (Review). Drug Dev Res 2001;53:193-207
8. Kaczmarek E, Koziak K, Sevigny J, et al. Identification and characterization of CD39 vascular ATP diphosphohydrolase. J Biol Chem 1996;271:33116-33122
9. Sevigny J, Sundberg C, Braun N, et al. Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 2002;99:2801-2809
10. Marcus AJ, Broekman MJ, Drosopoulos JHF, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet fonction is CD39. J Clin Invest 1997;99:1351-1360
11. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases. J Pharmacol Exp Ther 2003;305:9-16
12. Robson S, Schulte am Esch J II, Bach F. Factors in xenograft rejection. Ann N Y Acad Sci 1999;875:261-276
13. Buell G, Collo G, Rassendren F. P2X receptors-an emerging channel family (Review). Eur J Neurosci 1996; 8:2221-2228
14. Fredholm BB, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoreceptors. Pharmacol Rev 1994;46:143-152
15. Roman RM, Fitz JG. Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function (Review). Gastroenterology 1999;116:964-979
16. Palmer TM, Stiles GL. Adenosine receptors. Neuropharmacology 1995;34:683-694
17. Plesner L. Ecto-ATPases: identities and functions (Review). Int Rev Cytol 1995;158:141-214
18. Baurand A, Eckly A, Bari N, et al. Desensitization of the platelet aggregation response to ADP: differential downregulation of the P2Y1 and P2cyc receptors. Thromb Haemost 2000;84:484-491
19. Hourani SMO, Hall DA. Receptors for ADP on human blood platelets (Review). Trends Pharmacol Sci 1994;15: 103-107
20. Fijnheer R, Boomgaard MN, van den Eertwegh AJ, et al. Stored platelets release nucleotides as inhibitors of platelet function. Thromb Haemost 1992;68:595-599
21. Lages B, Weiss HJ. Enhanced increases in cytosolic Ca2+ in ADP-stimulated platelets from patients with delta-storage pool deficiency-a possible indicator of interactions between granule-bound ADP and the membrane ADP receptor. Thromb Haemost 1997;77:376-382
22. Enjyoji K, Sevigny J, Lin Y, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999;5:1010-1017
23. Goepfert C, Sundberg C, Sevigny J, et al. Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 2001;104:3109-3115
24. Zimmermann H. Two novel families of ectonucleotidases: molecular structure, catalytic properties and a search for function. Trends Pharmacol Sci 1999;20:231-236
25. Robson S, Sevigny J, Imai M, Enjyoji K. Thromboregulatory potential of endothelial CD39/nucleoside triphosphate diphosphohydrolase: modulation of purinergic signalling in platelets. Emerging Therapeutic Targets 2000;4:155-171
26. Zimmermann H. 5′-nucleotidase: molecular structure and functional aspects. Biochem J 1992;285:345-365
27. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 1998;161:95-109
28. Goding JW, Howard MC. Ecto-enzymes of lymphoid cells. Immunol Rev 1998;161:5-10
29. Kansas GS, Wood GS, Tedder TF. Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes. J Immunol 1991;146:2235-2244
30. Maliszewski CR, Delespesse GJ, Schoenborn MA, et al. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J Immunol 1994;153:3574-3583
31. Favaloro EJ. Differential expression of surface antigens on activated endothelium. Immunol Cell Biol 1993;71:571-581
32. Wang T-F, Guidotti G. CD39 is an ecto-(Ca2+, Mg 2+)-apyrase. J Biol Chem 1996;271:9898-9901
33. Pinsky DJ, Broekman MJ, Peschon JJ, et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 2002;109:1031-1040
34. Handa M, Guidotti G. Purification and cloning of a soluble ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Biochem Biophys Res Commun 1996;218:916-923
35. Schulte am Esch J II, Sevigny J, Kaczmarek E, et al. Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity. Biochemistry 1999;38:2248-2258
36. Wang TF, Guidotti G. Golgi localization and functional expression of human uridine diphosphatase. J Biol Chem 1998;273:11392-11399
37. Zimmermann H, Beaudoir AR, Boller M, et al. Nomenclature for two families of novel ectonucleotidases. In: Vanduffel, L., ed. Proceedings of the Second International Workshop on Ecto-ATPases and Related Ectonucleotidases. Maastricht, The Netherlands: Shaker Publishing BV; 2000:1-8
38. Zimmermann H, Braun N, Heine P, et al. Molecular and functional properties of E-NTPDase-1, E-NTPDase-2 and 5′-ectonucleotidase. In: Vanduffel, L., ed. Proceedings of the Second International Workshop on Ecto-ATPases and Related Ectonucleotidases. Maastricht, The Netherlands: Shaker Publishing BV; 2000:18-25
39. Wang TF, Handa M, Guidotti G. Structure and function of ectoapyrase (CD39). Drug Dev Res 1998;45:245-252
40. Chadwick BP, Frischauf AM. The CD39-like gene family-identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster. Genomics 1998;50:357-367
41. Mulero JJ, Yeung G, Nelken ST, Ford JE. CD39L4 is a secreted human apyrase, specific for the hydrolysis of nucleoside diphosphates. J Biol Chem 1999;274:20064-20067
42. Kaneider NC, Egger P, Dunzendorfer S, et al. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol 2002;22:894-900
43. Vigne P, Breittmayer JP, Frelin C. Analysis of the influence of nucleotidases on the apparent activity of exogenous ATP and ADP at P2Y(1) receptors. Br J Pharmacol 1998;125: 675-680
44. Sasamura H, Dzau VJ, Pratt RE. Desensitization of angiotensin receptor function. Kidney Int 1994;46:1499-1501
45. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s (Review). Nature 1993;362:801-809
46. Marcus AJ. Pathogenesis of atherosclerosis: special pathogenetic factors-inflammation and immunity: platelets. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven; 1996:607-637
47. Guerci B, Kearney-Schwartz A, Bohme P, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function (Review). Diabetes Metab 2001;27:425-434
48. Robson SC, Candinas D, Hancock WW, et al. Role of endothelial cells in transplantation (Review). Int Arch Allergy Immunol 1995;106:305-322
49. Platt JL, Lin SS, McGregor CGA. Acute vascular rejection. (Review). Xenotransplantation 1998;5:169-175
50. Platt JL. New directions for organ transplantation (Review). Nature 1998;392:11-17
51. Cotran RS, Pober JS. Effects of cytokines on vascular endothelium: their role in vascular and immune injury. Kidney Int 1989;35:969-975
52. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990;50:537-544
53. Bevalicqua MP, Gimbrone MAJ. Modulation of endothelial cell procoagulant and fibrinolytic activities by inflammatory mediators. In: Ryan US, eds. Endothelial Cells. Boca Raton, FL: CRC Press; 1988:107-118
54. Pober JS, Cotran RS. Cytokines and endothelial cell biology (Review). Physiol Rev 1990;70:427-451
55. Bach FH, Robson SC, Ferran C, et al. Endothelial cell activation and thromboregulation during xenograft rejection (Review). Immunol Rev 1994;141:5-30
56. Dalmasso AP. The complement system in xenotransplantation (Review). Immunopharmacology 1992;24:149-160
57. Baldwin WM, Pruitt SK, Brauer RB, Daha MR, Sanfilippo F. Complement in organ transplantation-contributions to inflammation, injury, and rejection (Review). Transplantation 1995;59:797-808
58. Murdoch C, Finn A. Chemokine receptors and their role in vascular biology (Review). J Vasc Res 2000;37:1-7
59. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury (Review). FASEB J 1994;8:504-512
60. Esmon CT. Cell mediated events that control blood coagulation and vascular injury (Review). Annu Rev Cell Biol 1993;9:1-26
61. Savage CO, Hughes CC, McIntyre BW, Picard JK, Pober JS. Human CD4+ T cells proliferate to HLA-DR+ allogeneic vascular endothelium. Identification of accessory interactions. Transplantation 1993;56:128-134
62. Murray AG, Khodadoust MM, Pober JS, Bothwell ALM. Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and co-stimulation by ligands for human CD2 and CD28. Immunity 1994;1:57-63
63. Bach FH, Robson SC, Ferran C, et al. Endothelial cell activation and thromboregulation during xenograft rejection (Review). Immunol Rev 1994;141:5-30
64. Crawford JM. Cellular and molecular biology of the inflamed liver (Review). Curr Opin Gastroenterol 1997;13: 175-185
65. Cotran RS, Pober JS. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol 1990;1:225-235
66. Bilzer M, Gerbes AL. Preservation injury of the liver: mechanisms and novel therapeutic strategies (Review). J Hepatol 2000;32:508-515
67. Game DS, Warrens AN, Lechler RI. Rejection mechanisms in transplantation (Review). Wien Klin Wochenschr 2001; 113:832-838
68. Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemia-reperfusion injury (Review). Am J Surg 2001;181: 160-166
69. Horie Y, Wolf R, Anderson DC, Granger DN. Hepatic leukostasis and hypoxic stress in adhesion molecule-deficient mice after gut ischemia/reperfusion. J Clin Invest 1997;99: 781-788
70. Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury (Review). Hepatology 2000;32:169-173
71. Cywes R, Mullen JB, Stratis MA, et al. Prediction of the outcome of transplantation in man by platelet adherence in donor liver allografts. Evidence of the importance of prepreservation injury. Transplantation 1993;56:316-323
72. Pinsky DJ, Yan SF, Lawson C, et al. Hypoxia and modification of the endothelium-implications for regulation of vascular homeostatic properties (Review). Semin Cell Biol 1995;6:283-294
73. Lu CY, Penfield JG, Kielar ML, Vazquez MA, Jeyarajah DR. Hypothesis: Is renal allograft rejection initiated by the response to injury sustained during the transplant process (Review). Kidney Int 1999;55:2157-2168
74. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH. The molecular basis of alloreactivity (Review). Immunol Today 1990;11:83-88
75. Bach FH. Reconsideration of the mechanism of first-set vascularized allograft rejection (Review). Hum Immunol 1990;28:263-269
76. Brindle N. Role of vascular endothelial cells in the allograft response. Eye 1995;9:167-172
77. Grey ST, Hancock WW. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein c by human mononuclear phagocytes. J Immunol 1996;156:2256-2263
78. Gamry ER Jr, Mehra MR. Transplantation 2004; 77(9 suppl):S68-S74
79. Demetris AJ, Murase N, Lee RG, et al. Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant 1997;2:27-44
80. Hosenpud JD. Immune mechanisms of cardiac allograft vasculopathy: an update. Transpl Immunol 1993;1:237-249
81. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14:387-397
82. Alexander RW. Oxidized LDL autoantibodies, endothelial dysfunction, and transplant-associated arteriosclerosis (Comment). Arterioscler Thromb Vasc Biol 2002;22:1950-1951
83. Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970;2:550-556
84. Sachs DH, Sykes M, Robson SC, Cooper DKC. Xenotransplantation (Review). Adv Immunol 2001;79:129-223
85. Bach FH, Winkler H, Ferran C, Hancock WW, Robson SC. Delayed xenograft rejection (Review). Immunol Today 1996;17:379-384
86. Robson SC, Cooper DKC, d'Apice AJF. Disordered regulation of coagulation and platelet activation in xenotransplantation (Review). Xenotransplantation 2000;7:166-176
87. Robson SC. Acute vascular rejection/delayed xenograft rejection and consumptive coagulopathy in xenotransplantation (Review). Curr Opin Organ Transplantation 2003;8:76-82
88. Imai M, Takigami K, Guckelberger O, et al. CD39/vascular ATP diphosphohydrolase modulates xenograft survival. Transplant Proc 2000;32:969
89. Candinas D, Koyamada N, Miyatake T, et al. Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions. Thromb Haemost 1996;76:807-812
90. Guckelberger O, Sun X, Sévigny J, et al. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost 2004;91:576-586
91. Jacobson J, Odlind B, Tufveson G, Wahlberg J. Effects of cold ischemia and reperfusion on trapping of erythrocytes in the rat kidney. Transplantation International 1988;1: 75-79
92. Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994;57:211-217
93. Adams DH, Wang L, Hubscher SG, Neuberger JM. Hepatic endothelial cells. Transplantation 1989;47:479-482
94. Neil DA, Adams DH, Gunson B, Hubscher SG. Is chronic rejection of liver transplants different from graft arteriosclerosis of kidney and heart transplants? Transplant Proc 1997;29:2539-2540
95. Clavien PA, Harvey P, Strasberg SM. Preservation and reperfusion injuries in liver allografts. Transplantation 1992;53:957-978
96. Clavien PA. Sinusoidal endothelial cell injury during hepatic preservation and reperfusion (Review). Hepatology 1998;28: 281-285
97. Pinsky DJ, Mehmet CO, Koga S, et al. Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest 1994;93: 2291-2297
98. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970;282:111-117
99. Colvin RB. The pathogenesis of vascular rejection. Transplant Proc 1991;23:2052-2055
100. Alexandre GP. From ABO-incompatible human renal transplantation to xenotransplantation. Xenotransplantation 2004;11:233-236
101. Billingham ME. Graft coronary disease-old and new dimensions. Cardiovasc Pathol 1997;6:95-101
102. Miyatake T, Koyamada N, Hancock WW, Soares MP, Bach FH. Survival of accommodated cardiac xenografts upon retransplantation into cyclosporine-treated recipients. Transplantation 1998;65:1563-1569
103. Lin Y, Soares MP, Sato K, et al. Accommodated xenografts survive in the presence of anti-donor antibodies and complement that precipitate rejection of naive xenografts. J Immunol 1999;163:2850-2857
104. Soares MP, Lin Y, Anrather J, et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 1998;4:1073-1077
105. Hancock WW, Gee D, de Moerloose P, et al. Immunohistochemical analysis of serial biopsies taken during human renal allograft rejection: changing profile of infiltrating cells and involvement of the coagulation system. Transplantation 1985;39:430-438
106. Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation (Review). Semin Hematol 1992;29:202-212
107. Platt JL, Bach FH. Discordant xenografting: challenges and controversies (Review). Curr Opin Immunol 1991;3:735-739
108. Platt JL. Xenotransplantation-recent progress and current perspectives (Review). Curr Opin Immunol 1996;8:721-728
109. Taniguchi S, Cooper D. Clinical xenotransplantation-past, present and future (Review). Ann R Coll Surg Engl 1997; 79:13-19
110. Goodman DJ, Pearse MJ, Dapice AJF. Overcoming hyperacute xenograft rejection with transgenic animals (Review). BioDrugs 1998;9:219-234
111. Dorling A, Lechler RI. Prospects for xenografting (Review). Curr Opin Immunol 1994;6:765-769
112. Dalmasso AP, Vercellotti GM, Fischel RJ, et al. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992;140:1157-1166
113. Galili U. Interaction of the natural anti-gal antibody with alpha-galactosyl epitopes-a major obstacle for xenotransplantation in humans. Immunol Today 1993;14:480-482
114. Cooper DKC, Ye Y, Niekrasz M, et al. Specific intravenous carbohydrate therapy-a new concept in inhibiting antibody-mediated rejection experience with ABO-incompatible cardiac allografting in the baboon. Transplantation 1993;56: 769-777
115. Cooper DKC, Koren E, Oriol R. α-galactosyl oligosaccharides and discordant xenografting. Xeno 1994;2:32-38
116. Rosengard AM, Cary NR, Langford GA, et al. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. A potential approach for preventing xenograft rejection. Transplantation 1995;59: 1325-1333
117. Sandrin MS, Fodor WL, Mouhtouris E, et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995;1:1261-1267
118. Sandrin MS, Fodor WL, Cohney S, et al. Reduction of the major porcine xenoantigen ga1-alpha(1,3)gal by expression of alpha(1,2)fucosyltransferase. Xenotransplantation 1996;3: 134-140
119. Byrne G, McCurry KR, Martin MJ, et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997;63:149-155
120. Diamond LE, Mccurry KR, Martin MJ, et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996;61: 1241-1249
121. Hancock WW. Delayed xenograft rejection. World J Surg 1997;21:917-923
122. Li Y, Csizmadia E, Sevigny J, Enjyoji K, Robson SC. CD39 (NTPDase1) modulates allograft rejection and cellular immune responses. American Journal of Transplantation 2003;3(suppl):545
123. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004;113:1440-1446
124. Bakker W, Mui K, van Son W. Detection of glomerular ischemia in chronic graft failure by quantification of the glomerular ectonucleotidase and ecto-ATPase. In: Vanduffel, L., ed. Proceedings of the Second International Workshop on Ecto-ATPases and Related Ectonucleotidases. Maastricht, The Netherlands: Shaker Publishing BV; 2000:44-49
125. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis (Review). J Biol Chem 2000;275:1521-1524
126. Imai M, Takigami K, Guckelberger O, et al. Modulation of nucleotide triphosphate diphosphohydrolase-1 (NTPDase1)/cd39 in xenograft rejection. Mol Med 1999;5:743-752
127. Imai M, Kaczmarek E, Koziak K, et al. Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells. Biochemistry 2000;38:13473-13479
128. Robson SC, Kaczmarek E, Siegel JB, et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997;185:153-163
129. Robson SC, Daoud S, Begin M, et al. Modulation of vascular ATP diphosphohydrolase by fatty acids. Blood Coagul Fibrinolysis 1997;8:21-27
130. Imai M, Takigami K, Guckelberger O, et al. Recombinant adenoviral mediated CD39 gene transfer prolongs cardiac xenograft survival. Transplantation 2000;70:864-870
131. Gangadharan SP, Imai M, Rhynhart KK, et al. Targeting platelet aggregation: CD39 gene transfer augments nucleoside triphosphate diphosphohydrolase activity in injured rabbit arteries. Surgery 2001;130:296-303
132. Dwyer KM, Robson SC, Nandurkar HH, et al. Inhibition of thrombosis in transgenic mice expressing human CD39. American Journal of Transplantation 2003;3(suppl):468
133. Koyamada N, Miyatake T, Candinas D, et al. Apyrase administration prolongs discordant xenograft survival. Transplantation 1996;62:1739-1743
134. Koziak K, Kaczmarek E, Kittel A, et al. Palmitoylation targets CD39/endothelial ATP diphosphohydrolase to caveolae. J Biol Chem 2000;275:2057-2062
135. Kittel A, Kaczmarek E, Sevigny J, et al. CD39 as a caveolar-associated ectonucleotidase. Biochem Biophys Res Commun 1999;262:596-599
136. Shaul PW, Anderson RGW. Role of plasmalemmal caveolae in signal transduction (Review). Am J Physiol Lung Cell Mol Physiol 1998;19:L843-L851
137. Hall RA, Ostedgaard LS, Premont RT, et al. A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci U S A 1998;95:8496-8501
138. Hung AY, Sheng M. PDZ domains: structural modules for protein complex assembly. J Biol Chem 2002;277:5699-5702
139. Saras J, Heldin CH. PDZ domains bind carboxy-terminal sequences of target proteins. Trends Biochem Sci 1996;21: 455-458
140. Nourry C, Grant SG, Borg JP. PDZ domain proteins: plug and play! (Review). Sci STKE 2003;2003:RE7
141. Fan JS, Zhang M. Signaling complex organization by PDZ domain proteins. Neurosignals 2002;11:315-321
142. Zhong XT, Malhotra R, Guidotti G. Regulation of yeast ectoapyrase Ynd1p activity by activator subunit Vma13p of vacuolar H+ -ATPase. J Biol Chem 2000;275:35592-35599
143. Wang DK, Li ZB, Messing EM, Wu G. Activation of Ras/ Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem 2002;277:36216-36222
144. Goepfert C, Imai M, Brouard S, et al. CD39 modulates endothelial cell activation and apoptosis. Mol Med 2000;6: 591-603
145. Erb L, Liu J, Ockerhausen J, et al. An RGD sequence in the P2Y(2) receptor interacts with alpha(V)beta(3) integrins and is required for G(0)-mediated signal transduction. J Cell Biol 2001;153:491-501
146. Teixeira A, Chaverot N, Schroder C, et al. Requirement of caveolae microdomains in extracellular signal-regulated kinase and focal adhesion kinase activation induced by endothelin-1 in primary astrocytes. J Neurochem 1999;72: 120-128
147. Mizumoto N, Kumamoto T, Robson SC, et al. CD39 is the dominant Langerhans cell associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med 2002;8:358-365